LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard ...
HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with ...
Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk 11.12.2024 / 07:29 CET/CEST The issuer is solely responsible for the content of this announcement. Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback